Job Description

Postdoctoral position in biomedical science is available in laboratories of Profs. Jolanta Grembecka and Tomasz Cierpicki, University of Michigan, Ann Arbor, to carry out cancer epigenetic projects focused on studying the effect of small molecules blocking new epigenetic targets and to pursue target validation studies using genetic approaches. The research will focus on evaluation of the activity and the mechanism of action of novel small molecules blocking epigenetic proteins in cancer as well as on evaluation of the effects of chromatin perturbation in cancer. We are seeking for a highly motivated postdoctoral fellow with extensive experience in cancer cell biology. This position requires the expertise in cell biology and molecular biology techniques, including PCR, qRT-PCR, Western Blotting, co-Immunoprecipitation, ChIP, ChIPSeq, flow cytometry. Prior work experience with animals such as transgenic mice and xenograft models of cancer are also required. Successful candidate will be a part of an interdisciplinary team focused on development and pre-clinical evaluation of novel anti-cancer drug candidates.

Requirements:
Applicant must have PhD in biology or related field. The candidates must be a first author on at least 2-3 publications. This position requires extensive experience in cell and molecular biology techniques as well as animal studies. Furthermore, excellent oral and written communication skills in English are required as well as the ability to conduct independent scientific investigations.

How to apply:
Please submit cover letter, CV, and contact information for 2-3 references combined into one PDF file by e-mail to: [email protected].

Contact: Jolanta Grembecka, PhD, Professor
Department of Pathology, University of Michigan
Ann Arbor, MI, 48109, USA
https://www.pathology.med.umich.edu/index.php?t=page&id=1473
e-mail: [email protected]

Relevant publications:
1. Klossowski, S. et al., Grembecka, J. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020 Feb 3;130:981.
2. Shukla, S. et al., Grembecka, J., Cierpicki, T. Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nat Chem Biol. 2021 Jul;17(7):784.
3. Miao, H., et al., Grembecka, J. Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. Blood. 2020 Dec 17;136:2958.